Evidence map›Paper›PMID 36522462›Full record

ArticleProstate cancer and prostatic diseases2023

Trends in prostate cancer mortality in the United States of America, by state and race, from 1999 to 2019: estimates from the centers for disease control WONDER database.

Chinmay Jani, Christian Mouchati, Nour Abdallah, Melissa Mariano, Ruchi Jani, Justin D Salciccioli, Dominic C Marshall, Harpreet Singh, Iris Sheng, Joseph Shalhoub and 1 more

Abstract read
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Observational
  4. Emerging Therapeutic Strategies in Metastatic Hormone-Sensitive Prostate Cancer.Journal of immunotherapy and precision oncology · 2026
    Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Chinmay Jani *Department of Internal Medicine, Mount Auburn Hospital, Cambridge, MA, USA. ctjani1494@gmail.com.ORCID 0000-0002-6917-5568
Christian Mouchati *School of Medicine, Case Western Reserve University, Cleveland, OH, USA.
Nour AbdallahDepartment of Urology Research, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, OH, USA.ORCID 0000-0003-2041-2806
Melissa MarianoDepartment of Internal Medicine, Mount Auburn Hospital, Cambridge, MA, USA.
Ruchi JaniSmt NHL Municipal Medical College, Ahmedabad, Gujarat, India.
Justin D SalciccioliHarvard Medical School, Boston, MA, USA.
Dominic C MarshallCritical Care Research Group, Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK.
Harpreet SinghDivision of Pulmonary and Critical Care, University of Wisconsin, Milwaukee, WI, USA.
Iris ShengDepartment of Internal Medicine, Mount Auburn Hospital, Cambridge, MA, USA.
Joseph Shalhoub *Academic Section of Vascular Surgery, Department of Surgery and Cancer, Imperial College London, London, UK.ORCID 0000-0003-1011-7440
Rana R McKay *University of California San Diego, San Diego, CA, 2021, USA.ORCID 0000-0002-0581-7963

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn the United States of America (USA), prostate cancer (PC) is the most common cancer in men and the second cause of cancer mortality. Black men (BM) have a higher incidence and worse mortality when compared to white men (WM). We compared trends in PC mortality in the USA by race and state from 1999 to 2019.

methodsWe extracted PC mortality data from the Centers for Disease Control (CDC) WONDER database using the International Classification of Diseases (ICD) 10 code C61. Age-Standardized Mortality Rates (ASMR) were divided into racial groups and reported by year and state. Due to the lack of available data in many states, analyses were conducted only for WM and BM using Joinpoint regression for trend comparisons.

resultsBetween 1999-2019, ASMR decreased at the national level in Black (-44.6%), Asian (-44.8%), White (-31.8%), and American Indian or Alaskan native men (-19.0%). ASMR decreased in all states for both races. The greatest drop in ASMR was in Kentucky (-47.0%) for WM and Delaware (-57.8%) for BM. In 2019, ASMRs in BM (13.4/100 000) were significantly higher than WM (7.3/100 000), American Indian or Alaskan Native (3.2/100 000), and Asian men (3.2/100 000) (p < 0.001). The highest ASMRs were in Nebraska (33.5/100 000) for BM and Alaska (11/100 000) for WM.

conclusionsDuring the last 20 years, the PC mortality rate dropped in all states for all races, suggesting an advancement in management strategies. Although a higher decrease in ASMR was observed in BM, ASMR remain higher among BM. ASMRs were also found to be increasing in many states post USPSTF guideline change (2012), indicating a need for more education around optimized prostate cancer screening.

Indexed as

Prostatic NeoplasmsAmerican Indian or Alaska NativeAsianBlack or African AmericanBlack PeopleCenters for Disease Control and Prevention, U.S.Early Detection of CancerHumansIncidenceMaleMortalityProstate-Specific AntigenUnited StatesWhiteProstate-Specific Antigen

Identifiers

PMID36522462

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.